Fredag 20 November | 22:02:56 Europe / Stockholm
Est. tid*
2027-08-05 08:05 Kvartalsrapport 2027-Q2
2027-05-05 08:05 Kvartalsrapport 2027-Q1
2027-02-11 08:00 Bokslutskommuniké 2026
2026-11-11 - Kvartalsrapport 2026-Q3
2026-08-05 - Kvartalsrapport 2026-Q2
2026-05-13 - X-dag ordinarie utdelning XSPRAY 0.00 SEK
2026-05-12 - Årsstämma
2026-04-28 - Kvartalsrapport 2026-Q1
2026-02-12 - Bokslutskommuniké 2025
2025-11-05 - Kvartalsrapport 2025-Q3
2025-08-15 - Kvartalsrapport 2025-Q2
2025-05-14 - X-dag ordinarie utdelning XSPRAY 0.00 SEK
2025-05-13 - Årsstämma
2025-05-07 - Kvartalsrapport 2025-Q1
2025-02-12 - Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-07 - Kvartalsrapport 2024-Q2
2024-05-22 - X-dag ordinarie utdelning XSPRAY 0.00 SEK
2024-05-21 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-02 - Kvartalsrapport 2023-Q2
2023-05-25 - Extra Bolagsstämma 2023
2023-05-16 - Årsstämma
2023-05-05 - X-dag ordinarie utdelning XSPRAY 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-05 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning XSPRAY 0.00 SEK
2022-05-19 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-10-26 - Kvartalsrapport 2021-Q3
2021-08-06 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning XSPRAY 0.00 SEK
2021-05-20 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-20 - Kvartalsrapport 2020-Q3
2020-07-31 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning XSPRAY 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-03-26 - Extra Bolagsstämma 2020
2020-02-28 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-23 - Årsstämma
2019-05-17 - X-dag ordinarie utdelning XSPRAY 0.00 SEK
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018
2018-11-28 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-16 - X-dag ordinarie utdelning XSPRAY 0.00 SEK
2018-05-14 - Årsstämma
2018-05-14 - Kvartalsrapport 2018-Q1
2018-02-20 - Extra Bolagsstämma 2017
2018-02-19 - Bokslutskommuniké 2017
2017-11-22 - Kvartalsrapport 2017-Q3
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Xspray Pharma är ett läkemedelsbolag med flera produktkandidater i klinisk utveckling som använder den patenterade HyNap-tekniken för att skapa förbättrade versioner av marknadsförda proteinkinashämmare. Läkemedelskandidaten Dasynoc® är en amorf form av dasatinib och genomgår en FDA-granskning för marknadsgodkännande. Bolagets produktportfölj inkluderar även XS003-nilotinib, XS008-axitinib och XS025-cabozantinib.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Xspray Pharma informs that FDA has completed its inspection of NerPharMa’s manufacturing facility

2026-11-20 16:13:00

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has been informed by its contract manufacturing NerPharMa that the U.S. Food and Drug Administration (FDA) has completed its follow-up inspection of NerPharMa’s manufacturing facility in Italy. The FDA is expected to determine the facility’s inspection classification within 90 days.

Consistent with the FDA inspection procedure, at the conclusion of the inspection, the FDA issued a Form FDA 483 containing observations to which NerPharMa will provide its written response by December 9, 2026. Observations are not graded by the FDA individually and it is not currently possible to determine what the outcome will be of the FDA’s holistic assessment of the inspection and the manufacturer’s actions. Nerpharma has confirmed that none of the observations specifically refer to Xspray’s manufacturing lines or the manufacturing of Dasynoc® or Nilopki®.

The FDA is expected to determine the facility’s inspection classification within 90 days, i.e. around mid-February 2027.

NerPharMa has confirmed that the work to address the observations is already under way. NerPharMa is fully committed to address the observations and will submit its response to the FDA by December 9, 2026.

“While we emphasize that the FDA has not yet reached a decision regarding the manufacturer's cGMP status, we are encouraged by NerPharMa’s commitment and pleased that the FDA process is progressing with a clear timeframe ahead. We will continue to work closely with NerPharMa and support them where appropriate. We remain focused on completing the work required to resubmit the NDAs for Dasynoc and Nilopki and anticipate the FDA's decision regarding NerPharMa,” says Blake Leitch, CEO of Xspray Pharma.

The plan to resubmit both NDAs during the fourth quarter of 2026 remains unchanged.

Xspray Pharma will inform the market when material new information is available.